1. Search Result
Search Result
Results for "

epithelial-mesenchymal transition (EMT)

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

4

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N7972

    Others Cancer
    19-Oxocinobufotalin is capable of suppressing EMT (Epithelial-mesenchymal transition) and weakening the migratory and invasive potential of PC3 cells .
    19-Oxocinobufotalin
  • HY-152084

    Others Cancer
    Anticancer agent 93 is a 4-Hydroxycoumarin derivative. Anticancer agent 93 can inhibit invasion and migration of lung cancer cells by modulating expression of epithelial-mesenchymal transition (EMT) effectors .
    Anticancer agent 93
  • HY-B0449
    Methacycline hydrochloride
    2 Publications Verification

    Bacterial Antibiotic Infection
    Methacycline hydrochloride is a tetracycline antibiotic and can inhibits bacterial protein synthesis. Methacycline hydrochloride is a potent epithelial-mesenchymal transition (EMT) inhibitor. Methacycline hydrochloride blocks EMT in vitro and fibrogenesis in vivo without directly affecting TGF-β1 Smad signaling. Methacycline hydrochloride is an antimicrobial and has the potential for pulmonary fibrosis .
    Methacycline hydrochloride
  • HY-128859

    Cytochrome P450 Metabolic Disease
    EMT inhibitor-2 (Compound 1) inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and TGF-β released from the immunocytes. EMT inhibitor-2 inhibits CYP3A4 testosteron and CYP2C9 with IC50s of 49.72 and 5.54 μM, respectively .
    EMT inhibitor-2
  • HY-152085

    Others Cancer
    Anticancer agent 94 is a 4-Hydroxycoumarin derivative. Anticancer agent 94 can inhibit invasion and migration of lung cancer cells by modulating expression of epithelial-mesenchymal transition (EMT) effectors .
    Anticancer agent 94
  • HY-151904

    TAM Receptor FLT3 PDGFR Cancer
    AXL-IN-13 is a potent and orally active AXL inhibitor (IC50: 1.6 nM, Kd: 0.26 nM). AXL-IN-13 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion .
    AXL-IN-13
  • HY-163178

    Apoptosis Autophagy Cancer
    Bisabosqual A, a potent asparagine synthetase (ASNS) inhibitor, with an IC50 of 10.7 μM. Bisabosqual A can covalently modify the K556 site of ASNS protein. Bisabosqual A promotes oxidative stress and apoptosis, while inhibiting autophagy, cell migration and epithelial-mesenchymal transition (EMT), impeding cancer cell development .
    Bisabosqual A
  • HY-153910

    Others Cancer
    AGPS-IN-1 (Compound 2i) is an effective AGPS binder. AGPS-IN-1 reduces ether lipids levels and cell migration rate. AGPS-IN-1 inhibits epithelial-mesenchymal transition (EMT) in prostate PC-3 and breast MDA-MB-231 cancer cells .
    AGPS-IN-1
  • HY-N10335
    Harringtonolide
    1 Publications Verification

    FAK Inflammation/Immunology Cancer
    Harringtonolide is a potent RACK1 inhibitor (IC50=39.66 μM in A375 cells). Harringtonolide inhibits the epithelial-mesenchymal transition (EMT) process and cell proliferation by affecting the interaction between FAK and RACK1. Harringtonolide has plant growth inhibitory, antiviral, anti-inflammatory, and antiproliferation activities .
    Harringtonolide
  • HY-N6896

    TGF-beta/Smad Cancer
    Isoviolanthin, a flavonoid glycoside, could markedly inhibit TGF-β1-mediated migration and invasion by deactivating epithelial-mesenchymal transition (EMT) via the TGF-β/Smad and PI3K/Akt/mTOR pathways in HCC cells. Isoviolanthin exhibits no cytotoxic effects on normal liver LO2 cells .
    Isoviolanthin
  • HY-12564

    Aurora Kinase Apoptosis Cancer
    Phthalazinone pyrazole is a potent, selective, and orally active inhibitor of Aurora-A kinase with an IC50 of 0.031 μM. Phthalazinone pyrazole can arrests mitosis and subsequently inhibit tumor growth via apoptosis of proliferating cells. Phthalazinone pyrazole suppresses the epithelial-mesenchymal transition (EMT) during the differentiation of hepatocyte-like cells (HLCs) from human embryonic stem cells .
    Phthalazinone pyrazole
  • HY-151976
    STAT3-IN-15
    1 Publications Verification

    STAT Inflammation/Immunology
    STAT3-IN-15 is a potent and orally active STAT3 inhibitor against idiopathic pulmonary fibrosis (IPF). STAT3-IN-15 inhibits STAT3 phosphorylation. STAT3-IN-15 also inhibits the migration and deformation of epithelial cells induced by TGF-β1 and inhibit epithelial-mesenchymal transition (EMT) .
    STAT3-IN-15
  • HY-138657

    Phosphatase Cancer
    NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor. NCGC00378430 partially reverses transcriptional and metabolic profiles mediated by SIX1 overexpression and reverses SIX1-induced TGF-β signaling and epithelial-mesenchymal transition (EMT). NCGC00378430 inhibits SIX1-mediated breast cancer metastasis in a mouse model .
    NCGC00378430
  • HY-147768

    PI3K Akt Microtubule/Tubulin MMP Apoptosis Cancer
    PI3K/AKT-IN-2 (Compound 12c) is a PI3K and AKT inhibitor. PI3K/AKT-IN-2 blocks the epithelial-mesenchymal transition (EMT) and induces apoptosis. PI3K/AKT-IN-2 inhibits the polymerization of tubulin .
    PI3K/AKT-IN-2
  • HY-151428

    Ferroptosis Apoptosis Bcl-2 Family COX Cancer
    Antitumor agent-78 is an antitumor agent, inhibits cancer cells growth and migration. Antitumor agent-78 triggers ferroptosis by inhibiting GPx-4 and elevating COX2. Antitumor agent-78 also activates intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) and hinders Epithelial-mesenchymal transition (EMT) process of cancer cells .
    Antitumor agent-78
  • HY-151429

    Apoptosis Ferroptosis Bcl-2 Family COX Cancer
    Antitumor agent-77 is an antitumor agent, inhibits cancer cells growth and migration. Antitumor agent-77 triggers ferroptosis by inhibiting GPx-4 and elevating COX2. Antitumor agent-77 also activates intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) and hinders Epithelial-mesenchymal transition (EMT) process of cancer cells .
    Antitumor agent-77
  • HY-151802

    TrxR Cancer
    CPUL1 is a TrxR inhibitor, which shows proliferation-inhibitory and anti-metastatic activity against A549 cells. CPUL1 influences EMT (epithelial-mesenchymal transition) via inducing ROS-mediated ERK/JNK signaling by inhibiting TrxR1 enzyme activity. CPUL1 in combination with α-Lipoic Acid (HY-N0492) or Dithiodipropionic acid (HY-W014395) is more effective .
    CPUL1
  • HY-149894

    Biochemical Assay Reagents Cancer
    MC-1-F2 is a FOXC2 inhibitor that reduces epithelial-mesenchymal transition (EMT) markers in breast cancer cells, suppresses cancer stem cell (CSC) properties and reduces invasiveness in castration-resistant prostate cancer (CRPC) cells. There is a synergistic effect between MC-1-F2 and Docetaxel, which has the potential to be used in combination to study CRPC .
    MC-1-F2
  • HY-123931
    ZLDI-8
    1 Publications Verification

    Notch Phosphatase Apoptosis Cancer
    ZLDI-8 is a Notch activating/cleaving enzyme ADAM-17 inhibitor and inhibits the cleavage of Notch protein. ZLDI-8 decreases the expression of pro-survival/anti-apoptosis and epithelial-mesenchymal transition (EMT) related proteins. ZLDI-8 is also a competitive and irreversible tyrosine phosphatase (Lyp) inhibitor with an IC50 of 31.6 μM and a Ki of 26.22 μM. ZLDI-8 inhibits the growth of MHCC97-H cells with an IC50 of 5.32 μM .
    ZLDI-8
  • HY-150596

    Apoptosis Bcl-2 Family JNK Cancer
    CT1-3 is a potent anticancer agent. CT1-3 induces mitochondria-mediated apoptosis by regulating JNK/Bcl-2/Bax/XIAP pathway. CT1-3 suppresses the epithelial mesenchymal transition (EMT) potential of human cancer cells (HCCs) via regulating the E-cadherin/Snail axis, thus inhibits tumorigenesis. CT1-3 has a strong antitumor effect in mice model and exhibits no significant hepatic and renal toxicity .
    CT1-3
  • HY-B0008

    MK-231

    NF-κB PD-1/PD-L1 Inflammation/Immunology Cancer
    Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .
    Sulindac
  • HY-B0008A

    MK-231 sodium

    NF-κB PD-1/PD-L1 Infection Inflammation/Immunology Cancer
    Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .
    Sulindac sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: